TBPH · Theravance Biopharma, Inc.
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Concurrent Repurchase Programs
| Authorized | As of | Remaining | Remaining as of | Source |
|---|---|---|---|---|
| $75,000,000 | 2023-02-28 | — | — | 10-K, filed 2024-03-01 |
| $250,000,000 | 2022-09-30 | — | — | 10-K, filed 2024-03-01 |
| $95,000,000 | 2022-09-28 | — | — | 10-K, filed 2024-03-01 |
Cash spent on buybacks by quarter
Cash deployed each quarter, with the average price paid where the company reported it. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2024-12-31 | $445,000 | 10-K, filed 2026-03-23 |
| 2023-12-31 | $197,051,000 | 10-K, filed 2025-03-07 |
| 2022-12-31 | $128,830,000 | 10-K, filed 2024-03-01 |